<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "https://foliamedica.bg/nlm/tax-treatment-NS0.dtd">
<article xmlns:tp="http://www.plazi.org/taxpub" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">87</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:A116C711-4C18-5A38-8F1E-5E97753A8A64</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Folia Medica</journal-title>
        <abbrev-journal-title xml:lang="en">FM</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0204-8043</issn>
      <issn pub-type="epub">1314-2143</issn>
      <publisher>
        <publisher-name>Plovdiv Medical University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/folmed.68.e144993</article-id>
      <article-id pub-id-type="publisher-id">144993</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Anatomy</subject>
          <subject>Neurology</subject>
          <subject>Surgery &amp; Invasive treatment</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Silent case of a gigantic high-grade glioma in the left temporoparietal region of the brain</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Coelho</surname>
            <given-names>Marina</given-names>
          </name>
          <email xlink:type="simple">marinargc@hotmail.com</email>
          <uri content-type="orcid">https://orcid.org/0009-0009-8667-7808</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Sousa</surname>
            <given-names>Henrique</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0001-7150-2329</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Mascarenhas</surname>
            <given-names>Tiago</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0005-2646-8247</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Avelar</surname>
            <given-names>Pedro</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Marques</surname>
            <given-names>Beatriz</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0000-3242-982X</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Henriques</surname>
            <given-names>Carla</given-names>
          </name>
          <uri content-type="orcid">https://orcid.org/0009-0004-1331-0785</uri>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Internal Medicine, Local Health Unit of Oeste - Torres Vedras, Portugal</addr-line>
        <institution>Local Health Unit of Oeste</institution>
        <addr-line content-type="city">Torres Vedras</addr-line>
        <country>Portugal</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p><bold>Corresponding author</bold>: Marina Raquel Gomes Coelho, ULS Oeste - Torres Vedras, Rua Dr. Aurélio Ricardo Belo, 2560 – 324, Torres Vedras, Lisboa, Portugal; Email: <email xlink:type="simple">marinargc@hotmail.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>06</month>
        <year>2026</year>
      </pub-date>
      <volume>68</volume>
      <issue>3</issue>
      <elocation-id>e144993</elocation-id>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/891FBA6E-3D75-599A-8271-5C457F4823F7">891FBA6E-3D75-599A-8271-5C457F4823F7</uri>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>12</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>04</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Marina Coelho, Henrique Sousa, Tiago Mascarenhas, Pedro Avelar, Beatriz Marques, Carla Henriques</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>High-grade gliomas are aggressive primary brain tumors that are extremely malignant, especially isocitrate dehydrogenase (<abbrev xlink:title="isocitrate dehydrogenase">IDH</abbrev>) wildtype glioblastoma. This case concerns a male 54-year-old with a history of substance abuse who was undervalued and diagnosed with a large glioblastoma following several months of inappropriate behavior. Although there has been some recent progress, a tumor of this size is still considered incurable and is currently a rare diagnosis in Western countries.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>C228T mutation</kwd>
        <kwd>glioblastoma</kwd>
        <kwd>high-grade glioma</kwd>
        <kwd>IDH</kwd>
        <kwd>TERT gene</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <sec sec-type="Citation" id="sec1">
        <title>Citation</title>
        <p>Coelho M, Sousa H, Mascarenhas T, Avelar P, Marques B, Henriques C. Silent case of a gigantic high-grade glioma in the left temporoparietal region of the brain. Folia Med (Plovdiv) 2026;68(3):е144993. <ext-link ext-link-type="doi" xlink:href="10.3897/folmed.68.e144993">doi: 10.3897/folmed.68.e144993</ext-link>.</p>
      </sec>
    </notes>
  </front>
  <body>
    <sec sec-type="Introduction" id="sec2">
      <title>Introduction</title>
      <p>High-grade gliomas are malignant, rapidly progressive primary brain tumors, with isocitrate dehydrogenase (<abbrev xlink:title="isocitrate dehydrogenase">IDH</abbrev>) wildtype glioblastoma being the most common in adults, as well as the most fatal.<sup>[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]</sup> Symptomatic presentation of brain tumors is non-specific, depending upon the location and size.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup> The most common symptoms of temporal-parietal lesions include memory impairment, speech disorders, seizures, visual field defects, and hallucinations.<sup>[<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]</sup></p>
    </sec>
    <sec sec-type="Case report" id="sec3">
      <title>Case report</title>
      <p><italic>A 54-year-old male with a history of drug, alcohol and tobacco abuse, and hepatitis C presented to the Emergency Room (<abbrev xlink:title="Emergency Room">ER</abbrev>) after being found unconscious with sphincter dysautonomia, most likely due to a postictal state. His relatives reported inappropriate behavior for the past three months, assumed to be a consequence of drug abuse. At admission he had global aphasia and grade four right hemiparesis. Computed tomography (<abbrev xlink:title="Computed tomography">CT</abbrev>) scan</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F2">1</xref>)</italic></bold><italic>and magnetic resonance imaging (<abbrev xlink:title="magnetic resonance imaging">MRI</abbrev>)</italic><bold><italic>(Fig. <xref ref-type="fig" rid="F1">2A, B</xref>)</italic></bold><italic>showed a large intra-axial left temporal lesion with a central soft tissue component and multiple peripheral cystic areas, with extensive perilesional vasogenic edema and signs of hydrocephalus with a marked deviation of the midline structures, consistent with a high-grade primary brain tumor. The patient was referred to neurosurgery, where a resection of the mass was performed. Postoperative <abbrev xlink:title="magnetic resonance imaging">MRI</abbrev> showed complete lesion resection with no complications, maintaining global aphasia and grade four hemiparesis. Pathology revealed wild-type <abbrev xlink:title="isocitrate dehydrogenase">IDH</abbrev> glioblastoma with a C228T mutation of the TERT gene promoter related to some resistance to radiotherapy. He was referred to a neuro-oncologist but missed all follow-up appointments. Six months later the tumor returned to its initial size</italic><bold><italic>(Figs <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F4">4</xref>)</italic></bold><italic>and the patient ultimately passed away</italic>.</p>
      <fig id="F2">
        <object-id content-type="arpha">FBBBBF75-A3B5-502C-B9A8-1547598641BA</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Axial view of contrast-enhanced <abbrev xlink:title="Computed tomography">CT</abbrev> scan from October 2023 showing a large lesion occupying space, predominantly temporal on the left, with cystic-necrotic uptake with adjacent edema. The lesion causes a marked mass effect, with a deviation of the midline structures to the right by approximately 28 mm.</p>
        </caption>
        <graphic xlink:href="foliamedica-68-3-e144993-g002.jpg" id="oo_1683918.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1683918</uri>
        </graphic>
      </fig>
      <fig id="F1">
        <object-id content-type="arpha">926F7C38-8552-5D59-9FF3-B56896F53BD0</object-id>
        <label>Figure 2.</label>
        <caption>
          <p><bold>A</bold> An axial view of contrast-enhanced <abbrev xlink:title="magnetic resonance imaging">MRI</abbrev> from October 2023 showing a large intra-axial expansive lesion in the left temporoparietal region with a soft tissue component and multiple peripheral cystic areas and extensive perilesional vasogenic edema. The lesion shows intense and homogeneous enhancement of the peripheral borders of the described cystic lesions, forming a complete regular ring. The described changes cause attenuation of the Sylvian fissure of the left cerebral hemisphere, with ipsilateral uncal herniation molding the brainstem and shaping the supratentorial ventricular system with features suggestive of encroachment on the right lateral ventricle atrium, along with mild ependymal transudation at the occipital horn, suggesting early hydrocephalus. Additionally, a marked deviation of the midline structures to the right is observed, about 1.5 cm at the level of the Monro foramina. <bold>B</bold> An axial view of contrast-enhanced <abbrev xlink:title="magnetic resonance imaging">MRI</abbrev> from October 2023 showing a lesion in the left temporoparietal region with punctate areas of abnormal enhancement after gadolinium administration, which may indicate small petechial hemorrhagic foci within the lesion.</p>
        </caption>
        <graphic xlink:href="foliamedica-68-3-e144993-g001.jpg" id="oo_1683919.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1683919</uri>
        </graphic>
      </fig>
      <fig id="F3">
        <object-id content-type="arpha">3E5ADBA1-C117-56FE-AE5B-C2DC305DB43C</object-id>
        <label>Figure 3.</label>
        <caption>
          <p>An axial view of the <abbrev xlink:title="Computed tomography">CT</abbrev> scan from February 2024 compared to the previous study from October 2023 revealed a postoperative cavity and currently multiple nodular lesions with heterogeneous contrast enhancement, particularly at the periphery, raising suspicion of tumor remnants.</p>
        </caption>
        <graphic xlink:href="foliamedica-68-3-e144993-g003.jpg" id="oo_1683920.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1683920</uri>
        </graphic>
      </fig>
      <fig id="F4">
        <object-id content-type="arpha">812BD79E-05EE-5037-A853-88D58667A57F</object-id>
        <label>Figure 4.</label>
        <caption>
          <p>An axial view of the <abbrev xlink:title="Computed tomography">CT</abbrev> scan from April 2024 that, in comparative analysis with the contrast-enhanced <abbrev xlink:title="Computed tomography">CT</abbrev> from February 2024, showed a marked dimensional increase of the necrotic cystic expansive lesion in the left cerebral hemisphere and its vasogenic edema, resulting in diffuse supratentorial sulcal attenuation, obliteration of the left Sylvian fissure, and encephalic herniation with a shift of midline structures to the right (approximately 2 cm at the level of the Monro foramina), along with descending uncal herniation of the left temporal lobe.</p>
        </caption>
        <graphic xlink:href="foliamedica-68-3-e144993-g004.jpg" id="oo_1683921.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/1683921</uri>
        </graphic>
      </fig>
    </sec>
    <sec sec-type="Discussion" id="sec4">
      <title>Discussion</title>
      <p>The authors present a case of a 54-year-old male patient who was diagnosed with a large glioblastoma at a late stage and had only six months of life following the diagnosis. This large tumor represents a rare diagnosis in Western countries at present.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
      <p>The majority of patients diagnosed with glioblastoma exhibit initial symptoms such as headaches, seizures, and cognitive dysfunction. Over time, these patients may also experience focal neurological signs. Contrarily, atypical presentations, including hallucinations, unconventional seizure patterns, pain syndrome, personality shifts, syncope episodes, vertigo, and distinctive focal neurological indications, such as dermatomal hypoesthesia or psychiatric manifestations, have been sporadically documented in the extant literature.<sup>[<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]</sup> While it is acknowledged that brain tumors may manifest with mild or non-specific symptoms, the size and the affected territory of the tumor in this case suggest an earlier onset and the presence of symptomatic epilepsy, focal neurological signs, and cognitive dysfunction.</p>
      <p>The unexpected mild clinical picture and late diagnosis were most likely caused by drug abuse, which masked neurologic signs and symptoms that had been present for several months, depending on the size and territory affected by the tumor.</p>
      <p>At the same time, the fact that the patient was not willing to undergo additional treatments and had been lost to follow-up emphasizes the importance of strong social support in allowing for more time with quality of life. Despite recent advances, glioblastoma is still an incurable tumor with an average survival time of six to 20 months, depending on treatment options.<sup>[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]</sup> In appropriately selected patients, aggressive surgery may relieve symptoms and prolong survival.<sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup></p>
    </sec>
    <sec sec-type="Conclusions" id="sec5">
      <title>Conclusions</title>
      <p>Large tumors of this kind are rare in nations with sophisticated neurology services and access to cutting-edge neuroimaging equipment. In this case report, the diagnosis was likely delayed due to the patient’s history of drug abuse, which made it challenging to distinguish neurological symptoms from behavioral issues. This highlights the importance of effective communication among psychiatrists, neurologists, and neuroradiologists, especially considering the tumor had been growing for several months without being detected.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation>Alzial G, Renoult O, Paris F, et al. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene [Internet] 2021;41(5):613–21. Available from: <ext-link xlink:href="https://www.nature.com/articles/s41388-021-02056-1.pdf" ext-link-type="uri">https://www.nature.com/articles/s41388-021-02056-1.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation>Alshiekh Nasany R, de la Fuente MI. Therapies for IDH-mutant gliomas. Curr Neurol Neurosci Rep 2023;23:225–233.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation>Melhem J, Detsky J, Mary Jane Lim-Fat, et al. Updates in IDH-wildtype glioblastoma. Neurotherapeutics 2022;19(6):1705–23.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation>Chandnani R, Anjankar A. Case of glioblastoma multiforme in the left temporoparietal region of the brain. Cureus 2022;14(8). <ext-link ext-link-type="doi" xlink:href="10.7759/cureus.28621">doi: 10.7759/cureus.28621</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation>Patel A, Biso GMNR, Fowler JB. Neuroanatomy, Temporal Lobe. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK519512/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK519512/</ext-link>.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation>Sanli AM, Turkoglu E, Dolgun H, et al. Unusual manifestations of primary glioblastoma multiforme: A report of three cases. Surg Neurol Internat 2010;1:87. doi: <ext-link xlink:href="10.4103/2152-7806.74146" ext-link-type="doi">https://doi.org/10.4103/2152-7806.74146</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation>Wilderson LR. A case report of parietal lobe glioblastoma and post-surgical neurosensory deficits. Clinical Insights in Eyecare. 2024;2(2). Available from: <ext-link xlink:href="https://clinicalinsightsineyecare.scholasticahq.com/article/94830" ext-link-type="uri">https://clinicalinsightsineyecare.scholasticahq.com/article/94830</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation>Mohammed S, Dinesan M, Ajayakumar T. Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study. Rep Pract Oncol Radiother 2022;27(6):1026-36. Available from: <ext-link xlink:href="9826661/" ext-link-type="pmcid">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826661/</ext-link>.</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation>Brown NF, Ottaviani D, Tazare J, et al. Survival outcomes and prognostic factors in glioblastoma. Cancers 2022; 4(13):3161.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation>McCutcheon IE, Preul MC. Historical perspective on surgery and survival with glioblastoma: how far have we come? World Neurosurgery 2021;149:148–68.</mixed-citation>
      </ref>
    </ref-list>
    <sec sec-type="Additional information" id="sec6">
      <title>Additional information</title>
      <p>
        <bold>Ethical statement</bold>
      </p>
      <list list-type="bullet">
        <list-item>
          <p>The authors declared that no clinical trials were used in the present study.
</p>
        </list-item>
        <list-item>
          <p>The authors declared that no experiments on humans or human tissues were performed for the present study.
</p>
        </list-item>
        <list-item>
          <p>The authors declared that no informed consent was obtained from the humans, donors or donors’ representatives participating in the study.
</p>
        </list-item>
        <list-item>
          <p>The authors declared that no experiments on animals were performed for the present study.
</p>
        </list-item>
        <list-item>
          <p>The authors declared that no commercially available immortalized human and animal cell lines were used in the present study.
</p>
        </list-item>
      </list>
      <p>
        <bold>Conflict of interest</bold>
      </p>
      <p>The authors have declared that no competing interests exist.</p>
      <p>
        <bold>Artificial Intelligence (AI) use</bold>
      </p>
      <p>The authors accept full responsibility for the content of the manuscript, including the disclosure of any use of AI. No AI tools were used in the preparation of this manuscript.</p>
      <p>
        <bold>Funding</bold>
      </p>
      <p>No funding was reported.</p>
      <p>
        <bold>Author contributions</bold>
      </p>
      <p>SR: conceptualization, supervision, data curation, and review; DPS and AVP: data curation; AV: manuscript preparation and revision.</p>
      <p>
        <bold>Author ORCIDs</bold>
      </p>
      <p>Marina Coelho <ext-link xlink:href="https://orcid.org/0009-0009-8667-7808" ext-link-type="uri">https://orcid.org/0009-0009-8667-7808</ext-link></p>
      <p>Henrique Sousa <ext-link xlink:href="https://orcid.org/0009-0001-7150-2329" ext-link-type="uri">https://orcid.org/0009-0001-7150-2329</ext-link></p>
      <p>Tiago Mascarenhas <ext-link xlink:href="https://orcid.org/0009-0005-2646-8247" ext-link-type="uri">https://orcid.org/0009-0005-2646-8247</ext-link></p>
      <p>Beatriz Marques <ext-link xlink:href="https://orcid.org/0009-0000-3242-982X" ext-link-type="uri">https://orcid.org/0009-0000-3242-982X</ext-link></p>
      <p>Carla Henriques <ext-link xlink:href="https://orcid.org/0009-0004-1331-0785" ext-link-type="uri">https://orcid.org/0009-0004-1331-0785</ext-link></p>
      <p>
        <bold>Data availability</bold>
      </p>
      <p>All of the data that support the findings of this study are available in the main text.</p>
    </sec>
  </back>
</article>
